News: Bayer AG (BAYRY.PK)

BAYRY.PK on OTC Markets Group

130.63USD
3:51pm EDT
Change (% chg)

$-4.96 (-3.66%)
Prev Close
$135.60
Open
$131.58
Day's High
$131.95
Day's Low
$130.59
Volume
47,797
Avg. Vol
69,274
52-wk High
$156.77
52-wk Low
$125.02

Search Stocks
Select another date:

Mon, Aug 31 2015

Photo

Bayer heart failure drug cuts deaths in mid-stage trial

- Bayer will move a heart failure drug into final-stage testing this year, boosting its ambitions in cardiovascular treatments after the experimental medicine showed a "striking" reduction in deaths in a mid-stage trial.

UPDATE 1-Bayer heart failure drug cuts deaths in mid-stage trial

* May launch in 2020/21, analysts see potential $2 bln sales (Updates with comment from lead investigator)

Bayer moves heart drug to final tests after mid-stage success

Aug 31 - Bayer will move a new heart failure drug into final-stage testing this year, boosting its ambitions in cardiovascular medicine, after the experimental medicine proved better than an older rival in a mid-stage trial.

Bayer One-A-Day plaintiffs beat dismissal of heart, immunity claims

- A federal judge in California has ruled that plaintiffs accusing Bayer of falsely stating that One-A-Day supplements can boost heart health and immunity have provided enough proof to survive the company's second bid to dismiss those claims.

BRIEF-Bayer says Covestro unit names CEO and CFO

* Says Covestro management board named: Patrick Thomas and Frank H. Lutz confirmed as ceo and cfo Further company coverage:

Bayer's MaterialScience open to M&A: Handelsblatt

FRANKFURT - MaterialScience, Bayer's plastics division, which plans to list on the stock exchange soon, could consider acquisitions, especially in polyurethane-related business, its head told a German paper.

Bayer's MaterialScience open to M&A -Handelsblatt

FRANKFURT, Aug 10 - MaterialScience, Bayer's plastics division, which plans to list on the stock exchange soon, could consider acquisitions, especially in polyurethane-related business, its head told a German paper.

German stocks - Factors to watch on August 10

FRANKFURT/BERLIN, Aug 10 - The DAX top-30 index looked set to open 0.5 percent higher on Monday, according to premarket data from brokerage Lang & Schwarz at 0602 GMT.

BRIEF-U.S. FDA approves Bayer's Finacea foam for rosacea

* FDA approves Bayer's Finacea (azelaic acid) foam for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea

Bayer says MaterialScience draws positive investor feedback

FRANKFURT, July 29 - Bayer's Chief Executive Marijn Dekkers told analysts in a conference call that the MaterialScience division's top management, which is preparing for a separate listing, has recently met with potential investors and received positive feedback.

Select another date:

Press Releases

Search Stocks